Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9285442 | 0.79 | KMT2A (0.33) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL14632256 | 0.78 | PRMT3 (0.33) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL21010284 | 0.77 | — | — | |
| SCHEMBL6897806 | 0.76 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL10596223 | 0.76 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL10101627 | 0.76 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL2980091 | 0.76 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL227850 | 0.75 | CYP3A4 (0.34) | — | |
| SCHEMBL5210963 | 0.75 | — | — | |
| SCHEMBL13397725 | 0.74 | PRMT3 (0.35) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | claimed |
| EP-1163212-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-31 | — | — | EP | claimed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | claimed |
| US-6794380-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; ANTIALLERGENS | ASTRAZENECA AB (SE) | 2004-09-21 | — | — | US | claimed |
| EP-1163237-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | claimed |
| EP-1115707-B1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | EP | claimed |
| US-20030186966-A1 | Amide derivatives | ASTRAZENECA AB | 2003-10-02 | — | — | US | claimed |
| US-6548514-B1 | Inhibitors of p38 kinase/cytokine suppressive binding protein (CSBP)/reactivating kinase (RK); 1-((pyridyl)aminocarbonyl)-3-((hetero)arylaminocarbonyl)benzene derivatives; treating cytokine related diseases and disorders | ASTRAZENECA AB (SE) | 2003-04-15 | — | — | US | claimed |
| JP-2002539187-A | — | — | 2002-11-19 | — | — | JP | claimed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | claimed |
| EP-1102743-B1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | claimed |
| EP-1163212-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | claimed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000055120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.I. (IT) | 2025-08-14 | — | — | US | disclosed |
| US-4189306-A | OCTANE RATING IMPROVERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-02-19 | — | — | US | disclosed |
| US-4180386-A | ANTIKNOCK FUEL ADDITIVES | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | KMT2A 2740/4885KDM4E 1496/4885PRMT3 601/4885 |
| US-20030186966-A1 | Amide derivatives | IL6, IL6ST, IFNG | KMT2A 2495/4885KDM4E 1166/4885PRMT3 216/4885 |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | CX3CR1, CCR2, CCR5 | KMT2A 3823/4885KDM4E 4831/4885PRMT3 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.